Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.
about
Why Your New Cancer Biomarker May Never Work: Recurrent Patterns and Remarkable Diversity in Biomarker FailuresProteomics of ovarian cancer: functional insights and clinical applicationsInterstitial fluid flow in cancer: implications for disease progression and treatment.Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery.Pathogenesis of ovarian cancer: clues from selected overexpressed genes.Deciphering the peptidome of urine from ovarian cancer patients and healthy controls.A new method for isolation of interstitial fluid from human solid tumors applied to proteomic analysis of ovarian carcinoma tissueIntegrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancerCirculating serum sVCAM-1 concentration in advanced ovarian cancer patients: correlation with concentration in ascites.Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.Molecular imaging of breast tumors using a near-infrared fluorescently labeled clusterin binding peptide.Proteomics and ovarian cancer: integrating proteomics information into clinical careUrinary signatures of Renal Cell Carcinoma investigated by peptidomic approaches.Bioinformatic identification of proteins with tissue-specific expression for biomarker discoveryReproducible quantification of cancer-associated proteins in body fluids using targeted proteomics.Deciphering the ovarian cancer ascites fluid peptidome.Screening and identification of biomarkers in ascites related to intrinsic chemoresistance of serous epithelial ovarian cancers.Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment.Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication.A novel peptide specifically targeting ovarian cancer identified by in vivo phage display.Nidogen-2: a new serum biomarker for ovarian cancerConfounding effects of hormone replacement therapy in protein biomarker studies.Measuring the intra-individual variability of the plasma proteome in the chicken model of spontaneous ovarian adenocarcinoma.Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity.Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism.Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression.IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer.A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancerOvarian cyst fluid is a rich proteome resource for detection of new tumor biomarkers.Identification of multiple novel protein biomarkers shed by human serous ovarian tumors into the blood of immunocompromised mice and verified in patient sera.Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer.Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes.Advances in membrane proteomics and cancer biomarker discovery: current status and future perspective.Lipoprotein lipase and phospholipid transfer protein overexpression in human glioma cells and their effect on cell growth, apoptosis, and migration.Mining the malignant ascites proteome for pancreatic cancer biomarkers.Functional proteomics of kallikrein-related peptidases in ovarian cancer ascites fluid.Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.Glycoproteomic Analysis of Malignant Ovarian Cancer Ascites Fluid Identifies Unusual Glycopeptides.Tetranectin positive expression in tumour tissue leads to longer survival in Danish women with ovarian cancer. Results from the 'Malova' ovarian cancer study.The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization.
P2860
Q24289009-1959DB35-9C24-4FCC-88E5-02BBEE8B91D6Q28082632-8C14C02F-5ED8-447C-A112-15FD25FA60FBQ30411142-5CD3C710-CBB5-4824-95A9-988D7375D49DQ30914170-2249E6AD-A343-4C4A-A8DC-796B6659FA02Q33651139-B0F65C13-773E-4FAC-BC4D-565EB2E24D1EQ33786098-F1886A2F-229B-4DA9-B8E4-DEC64DD8CA3AQ33889245-073076AE-200E-4C75-912F-CD456E7628BAQ33915144-D0590E6B-4C78-4AFC-9C02-7878196C0DD9Q33946367-BE6BAF10-096E-4030-87C4-2DB08486D332Q34033606-8C37FE29-298C-4789-8CA4-848863C95012Q34084282-B24355CB-2A5C-4EC0-A2EF-93FF74FE81F8Q34126627-E2B134B5-7663-4050-A46E-B02409C11976Q34155959-95F82DDE-9CE7-4EF6-B4A8-FCC3E1A782F2Q34239193-AEDF5A27-5A34-416C-918E-0ACF5F019511Q34333925-205896A1-2933-407F-BA75-A337C3E8018CQ34501478-B72498BB-80C9-4E87-AEB1-FB66AD698872Q34516315-217D1D4B-8F91-4A99-8F16-5B95FF5172A3Q34602948-2CA12D47-EB0C-41C4-B97C-0F711CC9F676Q34634997-255BF27C-9B85-4B62-A756-F8FEFFAEBCC9Q35012239-454193A5-71C7-4791-ACF2-4EA360E92139Q35030339-D03F343C-9D9F-484C-929C-3B893EB8D45AQ35051095-3FFD07C9-635B-428D-A9F1-E1B0B1E12D8EQ35118218-3803631D-AFB9-44D6-82A2-4619AE4CE8ABQ35216344-D314A9B2-A8C3-4CCA-8563-F6955C42EA5EQ35341853-C1BCA521-7F16-454F-B300-547A5E512AADQ35541079-06F90051-76B9-4F37-B365-D46278CFDB0CQ35735751-C4D474EA-8B6E-476D-BA20-28C830E0C97DQ35736782-B18602A3-1734-4656-8577-4F567B71F897Q36556482-D0D33C44-F90B-40DF-84A6-479AE6CDA0C6Q36721347-B31983E9-4AD9-4130-A9E9-D63D100D73CCQ37187957-BE0D3BE4-8FF5-4A3D-9377-14D6AF5E54C8Q37459618-82CDD6E6-2C51-404C-B90A-97E1A431A8ECQ38034447-13B13C7C-7E18-424E-8675-F3BB5C6D14F3Q38730202-6E3A7E81-5194-42E8-A840-A43B0AE56274Q39705901-097D6189-15EC-4DDA-B497-F65E822A0B74Q39735807-50317733-6528-48DF-98E1-90CA1F54BC9AQ41009650-D3F0B9A9-A142-4756-85C1-CB9EF32F9989Q41838773-01FD4863-7890-448E-8A2A-C59D12C78A6BQ42150435-9837EB43-8824-4A44-9BA8-D907E367E4A4Q42317468-15F661F5-BC18-4B87-A85A-0C9921A0E94E
P2860
Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.
@en
Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.
@nl
type
label
Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.
@en
Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.
@nl
prefLabel
Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.
@en
Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.
@nl
P2093
P2860
P1476
Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.
@en
P2093
C Geeth Gunawardana
Chris R Smith
Cynthia Kuk
Ihor Batruch
P2860
P304
P356
10.1074/MCP.M800313-MCP200
P577
2008-12-01T00:00:00Z